These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29914746)

  • 21. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
    Kuti JL; Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):53-5. PubMed ID: 26003469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
    Skoglund E; Ledesma KR; Lasco TM; Tam VH
    J Glob Antimicrob Resist; 2017 Dec; 11():154-155. PubMed ID: 29101084
    [No Abstract]   [Full Text] [Related]  

  • 27. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
    Tait JR; Harper M; Cortés-Lara S; Rogers KE; López-Causapé C; Smallman TR; Lang Y; Lee WL; Zhou J; Bulitta JB; Nation RL; Boyce JD; Oliver A; Landersdorfer CB
    Antimicrob Agents Chemother; 2023 Aug; 67(8):e0041423. PubMed ID: 37428034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
    So W; Shurko J; Galega R; Quilitz R; Greene JN; Lee GC
    J Antimicrob Chemother; 2019 Jan; 74(1):269-271. PubMed ID: 30295837
    [No Abstract]   [Full Text] [Related]  

  • 29. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R; Champion A; Reid DW
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
    MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO
    Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
    [No Abstract]   [Full Text] [Related]  

  • 34. Ceftolozane/tazobactam for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis adult patients: a case series.
    Ottino L; Bartalesi F; Borchi B; Bresci S; Cavallo A; Baccani I; Rossolini GM; Bartoloni A
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2211-2215. PubMed ID: 33709301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
    Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.
    Saran O; Sulik-Tyszka B; Basak GW; Wróblewska MM
    Med Sci Monit; 2019 Jan; 25():305-311. PubMed ID: 30628586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.
    Montero M; VanScoy BD; López-Causapé C; Conde H; Adams J; Segura C; Zamorano L; Oliver A; Horcajada JP; Ambrose PG
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.